Wall Street Bets Big On ARM, ACN, ANAB: Do Retail Investors Concur?

Wall Street analysts on Friday are seeing some exciting opportunities in the tech and biotechnology sectors, and doled out some positive notes. Let’s find out if retail investors are nodding to these cues.

Morgan Stanley Upgrades Arm (ARM) to Overweight: 

Analysts at Morgan Stanley are bullish on Arm Holdings PLC,citing the company's potential for growth in the emerging edge artificial intelligence (AI) space. They upgraded the stock from Equal Weight to Overweight and raised the price target to $190, up from $107. 

Retail investors on Stocktwits also seem to agree, with bullish sentiment (66/100) following the upgrade. One popular post even pointed out that the stock is "filling the first gap up at around $175" after the price target increase.

UBS Upgrades Accenture (ACN) to Buy: 

UBS upgraded Accenture Plc to Buy from Neutral, citing the company's opportunity for multiple expansion as the market anticipates accelerating revenue growth in AI. 

However, Stocktwits sentiment is more neutral (53/100) on ACN, possibly due to some hesitation over the company's recent acquisition spree — like Logic (a retail technology services firm) and True North Solutions (an industrial engineering solutions provider) — and recent underwhelming financial performance.

The company missed earnings estimates in its last quarter and its stock is down 4.60% year-to-date (YTD). It will be interesting to see if Accenture can meet analyst expectations and turn around investor sentiment.

JPMorgan Upgrades AnaptysBio (ANAB) to Overweight: 

JPMorgan upgraded AnaptysBio Inc to Overweight, with a price target of $69, up from $29. This significant upgrade reflects the potential of the company's lead candidate, rosnilimab. 

Rosnilimab is designed to treat rheumatoid arthritis and ulcerative colitis, and it has shown promise in clinical trials, according to Investing.com. Analysts are also particularly excited about the upcoming Phase 2b results for rosnilimab in rheumatoid arthritis, which are expected by mid-2025.

Retail investors on Stocktwits are also extremely bullish on ANAB (81/100), likely due to the recent upgrade and the potential for upside. Notably, JPMorgan's upgrade suggests a potential 103% upside from the current stock price.